Citius Pharmaceuticals, Inc. Financials
CTXR
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM ~2.4:1 split | SEP 2025 ~1.6:1 split | SEP 2024 | SEP 2023 | SEP 2022 ~1.3:1 split | SEP 2021 ~2.8:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $7 | – | – | – | $0 | $0 |
| Cost of Revenue | – | – | $17 | – | – | – |
| General & Administrative | $42 | $19 | $18 | $15 | $12 | $10 |
| Research & Development | $6 | $9 | $12 | $15 | $18 | $12 |
| Other Operating Expenses | – | – | – | – | $0 | $0 |
| Total Operating Expenses | $64 | $39 | $42 | $37 | $33 | $24 |
| Operating Income | -$59 | -$39 | -$42 | -$37 | -$33 | -$24 |
| Non-Operating | ||||||
| Net Interest Expense | -$0 | -$0 | $1 | $1 | $0 | $0 |
| Other Non-Operating Income (Expense) | $4 | $0 | $2 | $4 | $0 | $0 |
| EBT (Earnings Before Tax) | – | -$39 | -$39 | -$32 | -$33 | -$23 |
| Income Tax Expense | -$0 | $1 | $1 | $1 | $1 | $0 |
| Minority Interest | – | -$2 | -$0 | – | – | – |
| Net Income | ||||||
| Net Income | -$44 | -$37 | -$40 | -$33 | -$34 | -$23 |
| Per Share Data | ||||||
| Revenue Per Share | $0.27 | – | – | – | $0.02 | $0.02 |
| EPS (Basic) | -$2.92 | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 |
| EPS (Diluted) | -$2.92 | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 |
| Weighted Avg Shares (Basic) | 26.2M | 11.1M | 6.7M | 151.3M | 146.1M | 108.6M |
| Weighted Avg Shares (Diluted) | 26.2M | 11.1M | 6.7M | 151.3M | 146.1M | 108.6M |
| Shares Outstanding | 26.2M | 11.1M | 6.7M | 6.1M | 5.8M | 4.3M |
Citius Pharmaceuticals (CTXR) financials: revenue, profit and margins
Citius Pharmaceuticals (CTXR) generated about n/a in revenue and -$45 million in net income over the trailing twelve months, growing at roughly 12.5% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Citius Pharmaceuticals profitable?+
Citius Pharmaceuticals reported about -$45 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Citius Pharmaceuticals growing?+
Citius Pharmaceuticals's revenue has compounded at roughly 12.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside CTXR's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Fiscal year ends Sep.
Peers
Pharmaceutical Preparations · Pick stocks to compare with CTXR
Spot a number that looks wrong? Check it in CTXR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CTXR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.